The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) is a huge mover today! About 279,926 shares traded hands. Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has declined 59.01% since April 14, 2016 and is downtrending. It has underperformed by 63.70% the S&P500.
The move comes after 5 months negative chart setup for the $31.82M company. It was reported on Nov, 16 by Barchart.com. We have $3.22 PT which if reached, will make NASDAQ:PTX worth $3.50 million less.
Pernix Therapeutics Holdings Inc (NASDAQ:PTX) Ratings Coverage
Out of 4 analysts covering Pernix Therapeutics (NASDAQ:PTX), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Pernix Therapeutics has been the topic of 9 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) has “Strong Buy” rating given on Friday, August 7 by Needham. Brean Capital maintained the stock with “Buy” rating in Friday, March 11 report. The company was maintained on Tuesday, February 9 by Brean Capital. The rating was maintained by Brean Capital with “Buy” on Friday, August 7. The rating was downgraded by Oppenheimer to “Perform” on Thursday, March 17. The firm has “Hold” rating given on Friday, August 12 by Brean Capital. JMP Securities reinitiated the stock with “Market Outperform” rating in Wednesday, September 9 report. Needham downgraded Pernix Therapeutics Holdings Inc (NASDAQ:PTX) on Friday, March 11 to “Hold” rating.
According to Zacks Investment Research, “Pernix Therapeutics Holdings Inc., formerly known as Golf Trust of America, Inc., is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to meet medical needs primarily in pediatrics. The Company’s product families include Aldex, Pediatex, Z-Cof, Brovex, ReZyst and QuinZyme. Its ALDEX products are indicated for the treatment of allergies and symptoms of the common cold. PEDIATEX TD is for the treatment of respiratory allergies. Z-COF 8DM is for the treatment of allergies and symptoms of the common cold. The BROVEX products are indicated for the treatment of allergies and symptoms of the common cold. REZYST IM is a chewable tablet probiotic indicated to replace active cultures that are destroyed by diet and antibiotics and to reduce symptoms associated with irritable bowel syndrome and various gastrointestinal issues. QUINZYME is a dissolve tablet for patients with depleted ubiquinone levels and for patients on statin therapy. Pernix is based in Magnolia, Texas.”
Insitutional Activity: The institutional sentiment decreased to 0.34 in Q2 2016. Its down 0.41, from 0.75 in 2016Q1. The ratio dropped, as 38 funds sold all Pernix Therapeutics Holdings Inc shares owned while 21 reduced positions. 8 funds bought stakes while 12 increased positions. They now own 12.25 million shares or 66.36% less from 36.43 million shares in 2016Q1.
Oppenheimer & accumulated 0% or 14,700 shares. The New York-based Renaissance Limited Liability Company has invested 0% in Pernix Therapeutics Holdings Inc (NASDAQ:PTX). The Delaware-based Blackrock Advisors Ltd Liability Corp has invested 0% in Pernix Therapeutics Holdings Inc (NASDAQ:PTX). Moreover, Credit Suisse Ag has 0% invested in Pernix Therapeutics Holdings Inc (NASDAQ:PTX) for 160,687 shares. Wells Fargo And Mn holds 0% or 4,751 shares in its portfolio. Aqr Cap Mgmt Limited Liability Corp holds 0% or 1.44 million shares in its portfolio. Acadian Asset Management Limited accumulated 0% or 198,047 shares. Cambridge Investment Advsr holds 27,000 shares or 0% of its portfolio. Northern Corporation owns 74,680 shares or 0% of their US portfolio. Orbimed Advsr Limited Com owns 1.07 million shares or 0.01% of their US portfolio. Pnc Financial Service Grp Inc holds 0% or 551 shares in its portfolio. Ladenburg Thalmann Finance Incorporated has invested 0% of its portfolio in Pernix Therapeutics Holdings Inc (NASDAQ:PTX). Susquehanna Int Group Inc Limited Liability Partnership holds 108,424 shares or 0% of its portfolio. Millennium Management Ltd has 0% invested in the company for 260,033 shares. Goldman Sachs last reported 0% of its portfolio in the stock.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.